153 related articles for article (PubMed ID: 8080729)
1. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
2. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Int J Cancer; 1993 Dec; 55(6):1018-22. PubMed ID: 8253520
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cisplatin resistance in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
8. Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor.
Wen L; Hong D; Yanyin W; Mingyue Z; Baohua L
Arch Gynecol Obstet; 2013 May; 287(5):997-1004. PubMed ID: 23212665
[TBL] [Abstract][Full Text] [Related]
9. delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
McClay EF; Winski PJ; Jones JA; Jennerette J; Gattoni-Celli S
Cancer Res; 1996 Sep; 56(17):3866-9. PubMed ID: 8752147
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma.
McClay EF; McClay ME; Jones JA; Winski PJ; Christen RD; Howell SB; Hall PD
Cancer; 1997 Mar; 79(5):1037-43. PubMed ID: 9041168
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
12. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
Lenzi R; Frost P; Abbruzzese JL
Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
[TBL] [Abstract][Full Text] [Related]
14. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
15. Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
Nowak-Markwitz E; Maciejczyk A; Pudełko M; Tserenchunt G; Balázs G; Spaczyński M; Zabel M; Dietel M; Lage H; Surowiak P
Ginekol Pol; 2010 Mar; 81(3):183-7. PubMed ID: 20486538
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism.
Ercoli A; Scambia G; De Vincenzo R; Alimonti A; Petrucci F; Fattorossi A; Isola G; Benedetti Panici P; Caroli S; Mancuso S
Cancer Lett; 1996 Nov; 108(1):7-14. PubMed ID: 8950203
[TBL] [Abstract][Full Text] [Related]
17. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
18. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
Levasseur LM; Greco WR; Rustum YM; Slocum HK
Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
[TBL] [Abstract][Full Text] [Related]
19. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
20. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo].
Zhou Y; Chen H; Yang Q
Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]